The Role of Plasma Trough Concentration of Voriconazole and Voriconazole N-Oxide in Its Hepatotoxicity in Adult Patients

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2024 Aug 19

PMID 39156484

Authors

Lin Cheng

Xi You

Xiaowen Wang

Mingjie Yu

Changsheng Jia

Affiliations

Soon will be listed here.

Abstract

Objective: Hepatotoxicity is an important cause of early withdrawal of voriconazole (VCZ). The role of the plasma trough concentration of VCZ (C) in hepatotoxicity is confusion. VCZ N-oxide is the primary metabolite of VCZ in plasma. We investigated the role of VCZ C and plasma trough concentration of VCZ N-oxide (C) in hepatotoxicity in adult patients.

Materials And Methods: This was a prospective study. VCZ C and C were measured using liquid chromatography-tandem mass spectrometry.

Results: In total, 601 VCZ C and C from 376 adult patients were included. The percentage of grade 1 or higher adverse events for ALP, ALT, AST, γ-GT, and TBIL were 35.4%, 21.0%, 30.1%, 56.2%, and 22.2%, respectively. Compared with younger adult patients, elderly patients (≥65 years) had a higher rate of grade 1 or higher adverse events of ALP. In the multivariate analysis, VCZ C was a risk factor for grade 1 or higher adverse events of AST in elderly patients and TBIL in younger adult patients, and VCZ C was a risk factor for grade 1 or higher adverse events of ALT, AST, and TBIL. Results of the receiver operating characteristic curve analysis indicated that when the VCZ C was higher than 4.0 μg/mL, or the VCZ C was lower than 1.7 μg/mL, the incidence of grade 1 or higher adverse events of AST and TBIL increased.

Conclusion: VCZ C and C were associated with liver function-related adverse events. Measurement of VCZ C should be considered for VCZ therapeutic drug monitoring.

Citing Articles

Development, Analysis, and Determination of Pharmacokinetic Properties of a Solid SMEDDS of Voriconazole for Enhanced Antifungal Therapy.

Dewangan H, Sharma R, Shah K, Alam P Life (Basel). 2024; 14(11).

PMID: 39598215 PMC: 11595337. DOI: 10.3390/life14111417.

References

Wang T, Miao L, Shao H, Wei X, Yan M, Zuo X . Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study. Int J Antimicrob Agents. 2022; 60(5-6):106692. DOI: 10.1016/j.ijantimicag.2022.106692. View

Shen K, Gu Y, Wang Y, Lu Y, Ni Y, Zhong H . Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases. Ther Adv Drug Saf. 2022; 13:20420986221127503. PMC: 9549188. DOI: 10.1177/20420986221127503. View

Niioka T, Fujishima N, Abumiya M, Yamashita T, Ubukawa K, Nara M . Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes. Ther Drug Monit. 2017; 39(5):514-521. DOI: 10.1097/FTD.0000000000000441. View

Li X, Yu C, Wang T, Chen K, Zhai S, Tang H . Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2016; 72(10):1185-1193. DOI: 10.1007/s00228-016-2089-y. View

Jin H, Wang T, Falcione B, Olsen K, Chen K, Tang H . Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016; 71(7):1772-85. PMC: 4896404. DOI: 10.1093/jac/dkw045. View

Suzuki Y, Tokimatsu I, Sato Y, Kawasaki K, Sato Y, Goto T . Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity. Clin Chim Acta. 2013; 424:119-22. DOI: 10.1016/j.cca.2013.05.025. View

Taghvaye-Masoumi H, Hadjibabaie M, Ghadimi M, Zarif-Yeganeh M, Vaezi M, Ghavamzadeh A . Association of Voriconazole Trough Plasma Concentration with Efficacy and Incidence of Hepatotoxicity in Iranian Patients with Hematological Malignancies. Iran J Pharm Res. 2021; 20(1):62-71. PMC: 8170753. DOI: 10.22037/ijpr.2020.112330.13688. View

Lee J, Ng P, Hamandi B, Husain S, Lefebvre M, Battistella M . Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review. Ann Pharmacother. 2020; 55(4):509-529. DOI: 10.1177/1060028020948174. View

Zonios D, Yamazaki H, Murayama N, Natarajan V, Palmore T, Childs R . Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis. 2014; 209(12):1941-8. PMC: 4038142. DOI: 10.1093/infdis/jiu017. View

10.

Bogler Y, Stern A, Su Y, Lee Y, Seo S, Shaffer B . Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. Med Mycol. 2021; 59(10):970-979. PMC: 8487767. DOI: 10.1093/mmy/myab025. View

11.

Maertens J, Rahav G, Lee D, Ponce-de-Leon A, Ramirez Sanchez I, Klimko N . Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021; 397(10273):499-509. DOI: 10.1016/S0140-6736(21)00219-1. View

12.

Yamada T, Mino Y, Naito T, Kawakami J . Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients. J Infect Chemother. 2019; 25(12):1019-1025. DOI: 10.1016/j.jiac.2019.05.032. View

13.

Takesue Y, Hanai Y, Oda K, Hamada Y, Ueda T, Mayumi T . Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Clin Ther. 2022; 44(12):1604-1623. DOI: 10.1016/j.clinthera.2022.10.005. View

14.

Hamada Y, Ueda T, Miyazaki Y, Nakajima K, Fukunaga K, Miyazaki T . Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan. Mycoses. 2020; 63(8):779-786. PMC: 7496238. DOI: 10.1111/myc.13129. View

15.

Shang S, Cheng L, Li X, Xiang R, Yu M, Xiong L . Effect of CYP2C19 polymorphism on the plasma voriconazole concentration and voriconazole-to-voriconazole-N-oxide concentration ratio in elderly patients. Mycoses. 2020; 63(11):1181-1190. DOI: 10.1111/myc.13105. View

16.

Ullmann A, Aguado J, Arikan-Akdagli S, Denning D, Groll A, Lagrou K . Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018; 24 Suppl 1:e1-e38. DOI: 10.1016/j.cmi.2018.01.002. View

17.

Zhou Z, Yin X, Zhang Y, Shao Q, Mao X, Hu W . Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database. Front Pharmacol. 2022; 13:891336. PMC: 9098189. DOI: 10.3389/fphar.2022.891336. View

18.

Samanta P, Clancy C, Marini R, Rivosecchi R, McCreary E, Shields R . Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients. Clin Infect Dis. 2020; 73(3):416-426. PMC: 8326536. DOI: 10.1093/cid/ciaa652. View

19.

Patterson T, Thompson 3rd G, Denning D, Fishman J, Hadley S, Herbrecht R . Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4):e1-e60. PMC: 4967602. DOI: 10.1093/cid/ciw326. View

20.

Hanai Y, Hamada Y, Kimura T, Matsumoto K, Takahashi Y, Fujii S . Favorable Effects of Voriconazole Trough Concentrations Exceeding 1 μg/mL on Treatment Success and All-Cause Mortality: A Systematic Review and Meta-Analysis. J Fungi (Basel). 2021; 7(4). PMC: 8072959. DOI: 10.3390/jof7040306. View